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Abstract
·AIM: To determine the types and incidence of tumors
affecting the orbit, conjunctiva and lacrimal glands and
to study the trend line of these tumors in the United
States from 1973 to 2009.
·METHODS: We used the publicly available Surveillance,
Epidemiology and End Results (SEER) database
registries to determine the incidence rates. Age was
adjusted to the 2000 US Standard Population. Patients
were stratified according to age group, gender, race and
histological grouping of tumor lesions. Three age groups
were defined: 0-19, 20-49 and 逸50y. Annual percentage
changes were calculated to examine trends.
·RESULTS: The overall age adjusted incidence rate was
3.39 (95% CI: 3.27 -3.52) per million person -years. The
tumors were more prevalent in age group 逸50 counting
9.51 (95%CI: 9.11-9.92) per million person-years. Most of
the soft tissue sarcomas occurred in the young age with
incidence rate of 0.35 (95% CI: 0.28 -0.42) per million
person-years. Lymphomas were the dominant subtype in
the adult population with incidence rate of 5.74 (95%CI:
5.43-6.06) per million person-years. Incidence rates were
higher in males than females with an overall rate ratio of
1.31 (95%CI: 1.21-1.41) mainly caused by the increase in
carcinoma subtypes. White race had a higher tumor
incidence with a rate ratio of 1.47 (95% CI: 1.25 -1.73)
driven by the higher incidence of most histological
subtypes. Orbital tumors showed a higher incidence rate
followed by conjunctival and lacrimal gland tumors with
incidence rates of 1.59, 1.37 and 0.43 per million person-
years respectively. The trend line of overall incidence of
tumors showed a significant increase (APC=3.11, 95%CI:
2.61 -3.61) mainly due to increase of lymphomas. This
increase was higher than the increase of lymphomas at
other sites.
·CONCLUSION: Orbital, conjunctival and lacrimal gland
malignant tumors differ among children and adults. Over
the years there has been a noticeable increase in
incidence rates of orbital and lacrimal gland tumors
mainly caused by an increase in lymphomas and an
apparent increase due to advances in diagnostic
techniques. ICD -O -3 topographical coding should be
improved to consider the different orbital bones and
ocular structures.
· KEYWORDS: orbital tumors; incidence; conjunctiva;
lacrimal gland
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INTRODUCTION
O rbital lesions are frequently seen at ophthalmologyclinics, but malignant forms of such lesions constitute a
group of uncommon tumors. Many orbital, conjunctival and
lacrimal gland (OCLG) malignant tumors are not at first
suspected and thus initially misdiagnosed due to the lack of
proper diagnostic methods, presentation to a general
ophthalmologist and the lack of knowledge regarding the
frequency of such tumors. This lack of knowledge is evident
in paucity of literature covering the relative epidemiology
and prognosis of these tumors. This study focused on
incidence rates of OCLG malignant tumors. Only a few
studies have discussed population-based pattern of orbital
tumors incidence [1-2]. Most studies have focused on a special
histological subtype or a particular age group. Other studies
have investigated the population of a certain tertiary referral
center-thus possibly showing referral bias[3-5].
In this study, we aimed at discovering the differences in
incidence between malignant tumors originating from the
OCLG, using data from the Surveillance, Epidemiology and
End Results (SEER) Program database of the US National
Incidence of orbital malignant tumors in USA: 1973-2009
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Cancer Institute (NCI). Data analysis was carried out with a
focus on incidence rates according to different histological
categories-stratified by site, age, gender, and race.
SUBJECTS AND METHODS
The SEER database is a publicly available database covering
cancer cases in the United States. This database collects
patient information, including demographics, tumor site,
morphology, and stage as well as treatment course and follow
up survival data. In the database race is coded into three
categories; White, African American, and "other" (American
Indian native, Asian/Pacific). The "other" race category
refers to a heterogeneous group of patients each comprising a
small patient population and hence was removed during
analysis. SEER data cover almost 28% of US inhabitants.
Information from this data could be extrapolated from to
make conclusions regarding the entire US population[6]. Cases
in the current study were obtained from nine SEER registries
collected over the period between 1973 and 2009. The
SEER's nine registries are the Atlanta, Connecticut, Detroit,
Hawaii, Iowa, New Mexico, San Francisco-Oakland,
Seattle-Puget Sound, and Utah registries. Data for cases
diagnosed from 1973 and later are available in these
registries with the exception of the Seattle-Puget Sound and
Atlanta registries. These two joined the SEER program in
1974 and 1975, respectively. The nine registries used in this
study cover approximately 10% of the US population.
Population denominators used to calculate rates were
extracted from the NCI data. NCI data modifies the
population data produced by the US Census Bureau's
Population estimate program based on a collaboration with
the National Center of Health Statistics [7]. The SEER*Stat
program was used to calculate frequencies, incidence rates
and trends over time [7]. The database was accessed for data
extraction in August 2013. Tumor sites of interest were
identified and coded using the ICD-O3 codes as follows:
C69.0, conjunctival; C69.5, lacrimal gland and C69.6,
orbital. Similar histological subtypes were combined together
into 4 groups in addition to a fifth group of rare and other
unclassified malignant tumors. Only cases with known age
and malignant behavior were included. Population was
divided into 3 age categories: 0-19, 20-49 and 逸50 years of
age. Incidence rates were calculated per 1 000 000
person-years and age adjusted to the 2000 US Standard
Population (single ages-Census P25-1130); confidence
intervals (CIs) were set as 95% for rates and trends.
Percentage changes were calculated using one year for each
endpoint. Annual percentage changes (APC) were calculated
using the weighted least-squares method. The APC were
calculated based on the whole study duration. The principles
outlined in the Declaration of Helsinki (2008) were followed.
RESULTS
The number of patients identified as having OCLG tumors
were 2802 patients. The overall age-adjusted incidence rate
for OCLG malignant tumors was 3.39 (95%CI: 3.27-3.52)
per million person-years. The 逸50 age group had the highest
incidence rate of 9.51 per million person-years (95% CI:
9.11-9.92), while the 0-19 age group had the lowest
incidence rate of 0.56 per million person-years (95% CI:
0.47-0.66). Incidence rates of different histological subtypes
differed significantly between age groups. In the 0-19 age
group, soft tissue sarcomas comprised the most common
histological category with an incidence rate of 0.35 per
million person-years (95%CI: 0.28-0.42). However, in the
逸50 age group, the histological subtypes with the highest
incidence rate were lymphomas at a rate of 5.74 per million
person-years (95%CI: 5.43-6.06). Table 1 summarizes the
more common histological subtypes found in each of the
three age groups. Males had a statistically significantly higher
rate ratio for the overall incidence of OCLG malignant
tumors-compared to females of 1.31 (95% CI: 1.21-1.41).
This increase was mainly caused by the increase in carcinoma
subtypes in males [rate ratio 2.8 (95%CI: 2.36-3.32)].
There was a statistically significantly higher incidence rate
among Whites compared to African Americans with a rate
ratio of 1.47 (95%CI: 1.25-1.73). This higher incidence was
noted in most histological subtypes, especially melanomas
and carcinomas. The rate ratio for melanomas in the White
population compared to African Americans was 3.75 (95%
CI: 1.87-9.29), while that of carcinomas was 1.5 (95%CI:
1.08-2.14). Table 1 displays rate ratios of different
histological subtypes according to gender and race.
The incidence rate was statistically significantly higher for
orbital tumors at 1.59 per million person-years (95% CI:
1.50-1.68) compared with conjunctival tumors at 1.37 per
million person-years (95%CI: 1.30-1.46) and lacrimal gland
tumors at 0.43 per million person-years (95%CI: 0.39-0.48).
When the incidence rate of each histological category was
stratified according to site, carcinomas and melanomas were
statistically significantly higher in conjunctiva than orbit and
lacrimal glands. While for lymphomas, the orbit incidence
rate was statistically significantly higher than the conjunctival
and lacrimal gland rates. More details about the incidence
rates according to site are available in Table 2.
The trend line of disease showed significant increase over the
years. The annual percent change (APC) was a statistically
significant 3.11 (95% CI: 2.61-3.61). This increase was
mainly caused by an increase in lymphoma subtypes
(APC=4.8, 95% CI: 3.8-5.82). APC was also statistically
significant for melanomas and carcinomas but at lower
percent increase. Trend analysis stratified according to
gender showed that there was no statistically significant
difference between both genders. When the trend was
stratified according to race, APC could not be computed for
African Americans due to the small sample size. Table 3
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shows the APC for each histological category, with further
analysis stratified by race and gender. Subgroup analysis of
the trend in lymphoma subtypes was done. Table 4 shows a
significant rise of mature B-cell non-Hodgkin's lymphoma
over years (APC=5.82, <0.01). Incidence rates of different
histological subtypes and the overall incidence rates across
the years are displayed in Figure 1.
DISCUSSION
OCLG malignant tumors are more predominant among
adults. The 0-19 age group had the highest incidence rate of
Table 1 Common histology according to gender, race and age groups 
Gender Race Age category 
Histology Statistic 
M F Rate ratio White African American Rate ratio 0-19 20-49 ≥50 
Total (all age  
groups) 
Rate1 1.27 0.45 2.8a 0.80 0.54 1.5a 0.02 0.34 2.31 0.79 
95%CI 1.15-1.4 0.39-0.52 2.36-3.32 0.74-0.87 0.38-0.74 1.08-2.14 0.01-0.05 0.28-0.4 2.11-2.51 0.73-0.85 
Carcinomas 
Count 439 209  554 41  6 126 516 648 
Rate 0.48 0.39 1.22 0.47 0.13 3.75a 0.03 0.21 1.18 0.43 
95%CI 0.41-0.56 0.34-0.46 0.98-1.51 0.42-0.53 0.05-0.25 1.87-9.29 0.02-0.07 0.17-0.26 1.04-1.33 0.39-0.48 
Melanomas 
Count 177 180  328 8  9 80 268 357 
Rate 0.15 0.15 1.05 0.15 0.15 0.98 0.35 0.05 0.11 0.15 
95%CI 0.12-0.2 0.11-0.19 0.74-1.50 0.12-0.18 0.09-0.25 0.57-1.74 0.28-0.42 0.03-0.08 0.07-0.16 0.13-0.18 
Soft tissue sarcomas 
Count 70 67  106 18  91 22 24 137 
Rate 1.92 1.94 0.99 1.90 1.46 1.31 a 0.09 0.72 5.74 1.93 
95%CI 1.78-2.08 1.81-2.07 0.90-1.10 1.8-2.01 1.18-1.78 1.06-1.63 0.06-0.14 0.63-0.81 5.43-6.06 1.83-2.02 
Lymphomas and reticular 
malignancies 
Count 692 888  1307 103  25 261 1294 1580 
Rate 0.12 0.08 1.52 0.1 0.07 1.47 0.06 0.07 0.17 0.09 
95%CI 0.08-0.16 0.05-0.11 0.94-2.43 0.08-0.13 0.03-0.14 0.66-3.59 0.03-0.1 0.04-0.1 0.12-0.24 0.08-0.12 
Other rare and unclassified 
malignancies 
Count 44 36  68 8  16 27 37 80 
Rate 3.94 3.01 1.31a 3.43 2.34 1.47a 0.56 1.39 9.51 3.39 
95%CI 3.74-4.16 2.85-3.17 1.21-1.41 3.29-3.57 1.99-2.73 1.25-1.73 0.47-0.66 1.27-1.51 9.11-9.92 3.27-3.52 
Total 
Count 1422 1380  2363 178  147 516 2139 2802 
1Rates are per 1 000 000 and age-adjusted to the 2000 US Standard Population (19 age groups-Census P25-1130) standard; Confidence intervals (Tiwari mod) are 95% for 
rates and ratios. aThe rate ratio indicates that the rate is significantly different from the rate for the other comparison group (P<0.05). 
Table 2 Incidence rates according to site and histological category 
Site Statistic Carcinomas Melanomas Soft tissue sarcomas 
Lymphomas and reticular 
malignancies 
Other rare and unclassified 
malignancies Total 
Rate1 0.45 0.35 0.55 0.02 1.37 
95%CI 0.41-0.5 0.31-0.4 
0 
0.5-0.6 0.01-0.03 1.3-1.46 
Primary tumors 311 246 0 410 12 979 
Second tumors2 60 48 0 46 1 155 
C69.0-conjunctiva 
Total count 371 294 0 456 13 1134 
Rate 0.18 0 0.01 0.24 0 0.43 
95%CI 0.15-0.21 0-0.01 0-0.02 0.21-0.27 0-0.01 0.39-0.48 
Primary tumors 137 3 8 166 3 317 
Second tumors 12 0 0 33 0 45 
C69.5-lacrimal gland 
Total count 149 3 8 199 3 362 
Rate 0.16 0.07 0.14 1.14 0.08 1.59 
95%CI 0.13-0.19 0.06-0.09 0.12-0.17 1.06-1.21 0.06-0.1 1.5-1.68 
Primary tumors 105 50 121 785 60 1121 
Second tumors 23 10 8 140 4 185 
C69.6-orbit, NOS 
Total count 128 60 129 925 64 1306 
Rate 0.79 0.43 0.15 1.93 0.09 3.39 
95%CI 0.73-0.85 0.39-0.48 0.13-0.18 1.83-2.02 0.08-0.12 3.27-3.52 
Primary tumors 553 299 129 1,361 75 2417 
Second tumors 95 58 8 219 5 385 
Total 
Total count 648 357 137 1,580 80 2802 
1Rates are per 1 000 000 and age-adjusted to the 2000 US Standard Population (19 age groups-Census P25-1130) standard; Confidence intervals (Tiwari mod) are 95% for 
rates and ratios; 2“Second tumors” means that they are the second neoplasms after a primary one (later primary neoplasms). The primary neoplasms for those second tumors 
might be of different histology and/or in different sites. 
Incidence of orbital malignant tumors in USA: 1973-2009
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soft tissue sarcomas. This rate was mainly attributed to the
high rate of embryonal rhabdomyosarcoma in this age group.
According to the Cancer Incidence and Survival in Children
and Adolescent Rhabdomyosarcoma the incidence rate is 4.3
cases per million child, with 10% of them being orbital in site
(estimated to be 35 cases per year in US)[8].
Another longitudinal study of the years 1942-1959
highlighted 40 (73% ) children were diagnosed with
embryonal rhabdomyosarcoma (OER) out of a total of 55
children diagnosed with orbital tumors [9]. OER rise
embryonically as other rhabdomyosarcomas from fibers
imitating smooth muscles [10].
The results of this study are in alignment with others,
enabling us to conclude that OER presents commonly in the
younger age groups while being extremely rare in adults.
Additionally, the results of this study suggest no statistically
significant difference in incidence of OCLG soft tissue
sarcomas based on gender or race.
Lymphomas have the highest incidence of orbital
malignancies. We are able to note a rapidly rising trend with
a rise in rate. According to one review of 244 cases of OCLG
malignant tumors in Japan, malignant lymphoma was the
most common tumor-at 31%- in the >40 age group [4]. This
higher incidence rate was possibly due to environmental or
racial differences, or due to different techniques of diagnosis
of malignant lymphomas. Another study indicated that
incidence had tripled within the last 15y [11]. It had been
previously thought that this was due to an increase in
immunocompromised patients. However the incidence has
continued to increase whilst the number of
immunocompromised patients have been recently decreasing[11].
Another hypothesis connected this increase to the increase in
incidence of infections as with the Epstein Barr virus in HIV
negative patients [12]. Moreover, Toxoplasma gondii and
Chlamydia psittaci is often detected in cases of B-cell
lymphoma [13]. This hypothesis suggests that an antigenic
factor is the primary drive for B-cell expression. However,
another study of 200 patients above the age of 60 showed that
28% of patients with orbital tumors had lymphoma [14]. The
study connected the increased life expectancy in recent years
to the higher incidence rates of lymphoma.
The increasing incidence of lymphoma could be partially
attributed to new diagnostic methods which better diagnose
low grade lymphomas which were previously diagnosed as
pseudolymphomas [15]. But several other reviews have
Table 3 APC in each histological category stratified by gender and race 
Gender Histology Statistic 
M F 
Race white Total 
APCa 0.66 0.89 1.02b 0.80b Carcinomas 
95%CI -0.32 to 1.65 -0.14 to1.93 0.36-1.68 0.14-1.46 
APC -c -c 1.41b 1.28b Melanomas 
95%CI -c -c 0.35-2.49 0.19-2.39 
APC 4.45b 4.95b 4.60b 4.80b Lymphomas and reticular malignancies 
95%CI 3.25-5.66 3.77-6.15 3.63-5.59 3.80-5.82 
APC 2.61b 3.47b 3.03b 3.11b Total 
95%CI 1.9-3.33 2.83-4.12 2.51-3.55 2.61-3.61 
aAPC: Annual percent change is calculated using weighted least squares method; bThe confidence interval indicates that the annual 
percent change is statistically significant different than zero; cStatistics could not be computed here beside soft tissue sarcomas, 
other rare and unclassified malignancies and African American race due to small sample size. 
Table 4 Incidence rates of lymphoma broad groupings over years 
Lymphoma broad grouping (rate) 
Year of 
diagnosis Malignant lymphomas, NOS or diffuse 
NHL-mature B-cell 
lymphomas 
Plasma cell  
tumors 
APC 1.27 (P=0.12) 5.82 (P<0.01)  
1975-2009 0.44 1.51 0.02 
1975-1984 0.27 0.39 0 
1985-1994 0.49 1.03 0.01 
1995-2004 0.58 2.19 0.03 
2005-2009 0.31 2.39 0.03 
APC: Annual percent change. Rates are per 1 000 000 and age-adjusted to the 
2000 US Standard Population (19 age groups-Census P25-1130) standard. 
Malignant lymphomas as per codes 9590-9599, NHL-mature B-cell lymphomas 
as per codes 9670-9699 and plasma cell tumors as per codes 9730-9739. 
 
Figure 1 Incidence rates of different histological subtypes and
the overall incidence rate across the years from 1975 to 2009
RMS: Rhabdomyosarcoma.
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confirmed the unexplained increasing incidence of all
subtypes of lymphoma [16-17]. Our data show a steady annual
increase of most subtypes of lymphoma in the OCLG which
warrants further etiological studies. However, mature B-cell
lymphomas showed the only significant increase over years.
This is probably the subtype that leads the trends showed in
other papers [18-19].
Our results indicate that there is no statistically significant
difference in incidence rate of lymphomas according to
gender comparable to two recent publications[15,19].
Carcinomas were the second most common histological type
in our series. Most patients were above 50 years of age. The
majority of cases suffered from squamous cell carcinoma,
occurring predominantly in the conjunctiva. We noted that
carcinomas show a statistically significantly higher incidence
rate in males than females. These findings are inconsistent
with the cancer statistics published by the American Cancer
Society in 2010, which estimated the number of new cases of
eye and orbital tumors to be the same-irrespective of
gender [20]. However, Our results are consistent with a skin
cancer study conducted at 2002 [21] and another study from the
Netherlands [2]. The underlying reason for this may be due to
higher sun exposure in males compared with females;
possibly due to occupational differences [22]. Another recent
study comparing gender impact on incidence of squamous
cell carcinoma (SCC) in healthcare workers concluded that
male incidence rates were higher than females [23]. It also
noted that head and neck SCC were about 48%-60% of total
SCC. In addition, it stated that the European standardized
rates for male incidence was 22.2 to 35.4 per 100 000 and 7.8
to 20.5 for females. This was confirmed by other studies [24].
Conversely, one study studying association between
ultraviolet ray exposure and squamous cell carcinoma
showed a higher incidence in females compared to males in
many anatomical sites [24]. The later study requires more
correlation with demographics, pattern of work and sun
exposure habits.
Carcinomas show a higher incidence rate in whites compared
with African Americans. Other studies focused mainly on
white populations[25].
Melanomas show its highest incidence rate in the 逸50 age
group, whites and in the conjunctiva. Melanomas show no
statistically significant difference in incidence rate based on
gender. A recent study identified the incidence of ocular
melanoma to be 5.6 patients per million person-years-a very
low value when compared with cutaneous disease. That study
however did not discuss orbital affection [26]. In later study
there was a lower age-adjusted incidence of cutaneous and
ocular melanomas in women. The increasing incidence of
conjunctival melanoma over years was noted by other
studies[27] in contrast to ocular melanomas[26,28].
Examining the trend of OCLG malignant tumors reveals a
significant increase across the years (Table 3). This increase
has been brought about in the form of an increase in
lymphomas subtypes. Other histological subtypes have also
shown a statistically significant annual percent increase in
incidence rates, but this was not as marked as in the case of
lymphomas (Figure 1). Incidence rates of lymphomas are
already shown to have been increasing at most sites across
the years, but at lower rates[29]. A slight drop was observed in
the last five years. The higher rates of increase of lymphomas
in orbit and lacrimal glands compared with other sites should
be further studied. We believe that this study will help
ophthalmologists during diagnosis and patient counselling by
considering all tumors that affect the ocular adnexa and
comparing them together in standardized settings. Furthermore,
our findings can be correlated with future systemic
prospective studies. Our study carries the limitations of SEER
data usage that were described else-where [30-31]. Moreover,
ICD-O-3 coding has limited capability of representing eye
lid, structures of the eye, adnexa and orbital bones[32].
In summary, primary malignant tumors at OCLG sites
comprise numerous histological subtypes. They mainly affect
adults, and do so with different histologies than those
affecting children. This study concludes that lymphomas are
the most common primary malignant orbital tumor in the US,
followed by carcinomas, melanomas and
rhabdomyosarcomas. The overall trend of orbital malignant
tumors has been increasing and this is attributed mainly to the
rising incidence rates of lymphomas. Incidence rates
differences are observed between genders with a higher
overall male incidence due to differences in incidence of
carcinomas. There is also a significantly higher incidence rate
among Whites compared with African Americans;
predominantly due to increased incidence of melanomas and
carcinomas among the former. We recommend further
studies focusing on demographic and geographic factors,
exposure to ultraviolet rays and to carcinogens, and the effect
of habits and the role of genetics on incidence rates of OCLG
malignant tumors.
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